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Women who experience pre-eclampsia or hypertension during pregnancy may have a reduced risk for breast cancer later in
life. The evidence is based on case–control studies, and here we report the results of a cohort study exploring the link
between pre-eclampsia and gestational hypertension diagnosed in the ﬁrst pregnancy and subsequent risk for breast cancer.
We combined information from the Medical Birth Registry and the Cancer Registry in Norway, which are both nation-wide.
Between 1967, when the birth registry was established, and 1998, 694657 women were recorded with a ﬁrst birth, and
classiﬁed according to whether pre-eclampsia and/or hypertension was diagnosed in the ﬁrst pregnancy. Linkage to the
Norwegian Cancer Registry identiﬁed 5474 new cases of breast cancer diagnosed subsequently to their ﬁrst delivery.
Compared to other parous women, women with pre-eclampsia and/or hypertension diagnosed in their ﬁrst pregnancy had
19% lower risk (95% conﬁdence interval, 9 to 29%) for breast cancer, after adjustment for attained age, calendar period of
diagnosis, age at ﬁrst birth, and parity. This result was similar for term and preterm deliveries, across the range of offspring
birth weight, and for pre- and postmenopausal women. These results suggest that the pathophysiology surrounding pre-
eclampsia and gestational hypertension plays an important role in breast cancer etiology. A better understanding of the
underlying processes could provide an insight into the pathogenesis of breast cancer.
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Several risk factors for breast cancer have been identiﬁed (Kelsey,
1993), but few of them are linked to identiﬁable mechanisms that
allow a clear insight into the natural history of breast cancer. There
have been studies indicating that pre-eclampsia or hypertension in
pregnancy is associated with subsequent reduction in breast cancer
risk in the mother (Polednak and Janerich, 1983; Troisi et al, 1998;
Thompson et al, 1989; Cohn et al, 2001). If conﬁrmed, this asso-
ciation could be particularly useful in understanding the
pathogenesis of breast cancer (Hoover and Troisi, 2001), because
pre-eclampsia has an identiﬁable, if not yet fully identiﬁed, patho-
physiology (Roberts and Cooper, 2001). The earlier investigations
of the association of pre-eclampsia or pregnancy hypertension with
breast cancer risk (Polednak and Janerich, 1983; Thompson et al,
1989; Troisi et al, 1998; Cohn et al, 2001), however, have all had
a case–control design that is not immune to subtle biases. We
report here the results of a cohort study exploring the link between
pre-eclampsia and/or hypertension in pregnancy and subsequent
breast cancer risk in the mother.
MATERIALS AND METHODS
Data were derived from the Norwegian Medical Birth Registry that
comprises all births since 1967, and the Norwegian Cancer Regis-
try, which has registered incident cancers since 1953. Midwives
and doctors have to ﬁll in a standardised form to notify the birth
registry about each birth that takes place in the country, and the
reporting of cancer by doctors or hospital departments to the
cancer registry is also mandatory. The unique identiﬁcation
number of Norwegian citizens enabled linkage between the birth
registry and the cancer registry for cancer follow-up.
We have identiﬁed cases of pre-eclampsia and/or hypertension
induced by pregnancy as indicated in the standardised form, and
the women were accordingly categorised as having been diagnosed
with at least one of these conditions (Lie et al, 1998). In the
analyses, we further subdivided the women according to whether
they had a premature delivery (537 weeks’ gestation) or not,
according to offspring’s birth weight (in three categories: small,
appropriate, or large for gestation), and according to age at diag-
nosis (cut-off at 50 years to approximate pre- and
postmenopausal status).
We used each woman’s identiﬁcation number to link the women
registered at the medical birth registry to the national cancer regis-
try in order to identify women who had developed cancer
subsequent to giving birth. In total, 756414 women have been
recorded with a ﬁrst birth in the birth registry between 1967 and
1998. Of these, 1556 women were excluded from analysis, either
because they had a diagnosis of cancer recorded prior to their ﬁrst
birth, or because they had emigrated and could not be traced
during follow-up. We also excluded 60201 women who had
incomplete information on offspring birth weight or length of
gestation at birth. Thus, we have followed 694657 women from
their ﬁrst birth until the diagnosis of cancer, until death from
any cause, or to the end of follow-up (December 31, 1998), which-
ever occurred ﬁrst.
We compared breast cancer risk in women who had experi-
enced pre-eclampsia and/or hypertension induced by their ﬁrst
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attained age (nine categories), calendar period of diagnosis (three
categories), age at ﬁrst birth (ﬁve categories), and total number of
births (ﬁve categories). In the multivariate analyses, we applied
Poisson regression modelling, using the Epicure software (Epicure,
Seattle, WA, USA: Hirosoft Int Corp, 1993), and we used SPSS,
version 10.05 (SPSS, Inc., Chicago, IL, USA), for the descriptive
analyses.
RESULTS
During follow-up, 5474 cases of breast cancer were diagnosed
among the 694657 parous women. Of these cases, 280 occurred
among women who were diagnosed with pre-eclampsia and/or
hypertension in their ﬁrst pregnancy. These women had a 19%
lower risk of subsequent breast cancer than the remaining women
(rate ratio 0.81, 95% conﬁdence interval 0.71 to 0.91), after adjust-
ment for attained age, calendar period of diagnosis, age at ﬁrst
birth, and parity (Table 1).
We explored whether the association between pre-eclampsia and
breast cancer risk could be modiﬁed by length of gestation
(preterm or term delivery), offspring birth weight, or the woman’s
age (cut-off at 50 years). The results show that the pre-eclampsia-
related reduction of breast cancer risk did not substantially differ
across these subgroups (Table 2).
DISCUSSION
We found that women who were diagnosed with pre-eclampsia
and/or hypertension in their ﬁrst pregnancy were at reduced risk
of breast cancer, compared to other women who did not develop
pre-eclampsia or hypertension during their ﬁrst pregnancy. The
inverse association has also been found in the previously reported
case–control studies (Polednak and Janerich, 1983; Troisi et al,
1998; Thompson et al, 1989; Cohn et al, 2001).
The prospective nature of this study all but excludes selection or
information bias as plausible explanations for the ﬁndings, and the
large number of women makes it unlikely that chance can play an
important role.
The clinical manifestations of pre-eclampsia are heterogeneous,
and this could indicate that the condition comprises different
biological entities (Ness and Roberts, 1996). If so, one might expect
that the association between pre-eclampsia and breast cancer risk
would differ among subtypes of pre-eclampsia. However, by
exploring the association between different characteristics of pre-
eclampsia and breast cancer risk, we found that the reduced risk
for breast cancer was consistent between term and preterm deliv-
eries, across the range of the offspring’s birth weight, and
between pre- and postmenopausal women.
Our analysis focused on the ﬁrst pregnancy, with adjustment for
total ascertainable parity. Although less common, some women will
have developed pre-eclampsia or hypertension also during higher
order pregnancies, and because of this, the pre-eclampsia-related
protection against breast cancer in our study could have been
somewhat underestimated.
A central characteristic of pre-eclampsia is an abnormal implan-
tation that has been attributed to a shallow connection between the
placenta and the endometrium (Roberts and Cooper, 2001). A
combination of genetic susceptibility and abnormal placentation
is thought to constitute the basis for pre-eclampsia, and clinically,
the syndrome is characterised by hypertension and proteinuria. In
women who develop pre-eclampsia, there may be a disturbance in
the fundamental balance between steroid and other pregnancy
hormones, with relatively lower oestrogen, and higher androgen
levels (Innes and Byers, 1999). Since pre-eclampsia conveys some
protection against breast cancer risk, a better understanding of
its pathophysiology could also provide an insight into the patho-
genesis of breast cancer.
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Table 2 Rate ratio
a of breast cancer in relation to pre-eclampsia and/or hypertension in the ﬁrst pregnancy, stratiﬁed by time of delivery, offspring birth
weight, and age at diagnosis of the woman
Delivery Offspring birth weight Age at diagnosis
Preterm Term Small Average Large 550 years 550 years
rate ratio rate ratio rate ratio rate ratio rate ratio rate ratio rate ratio
Normotensive 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Pre-eclampsia/hypertension 0.88 0.79 0.78 0.81 0.88 0.81 0.81
95% CI
b 0.6–1.2 0.7–0.9 0.7–0.9 0.7–1.0 0.7–1.2 0.7–0.9 0.6–1.1
aAdjusted for attained age (530, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–80), calendar period of diagnoses (1967–76, 1977–86, 1987–98), age at ﬁrst
birth (520, 20–24, 25–29, 30–34, 35–54), and parity (1, 2, 3, 4, 5–16).
bCI=conﬁdence interval
Table 1 Pre-eclampsia and/or hypertension diagnosed in the ﬁrst pregnancy and subsequent risk for breast cancer
Person years Cases of breast cancer Rate ratio
a 95% CI
b
Women without pre-eclampsia or hypertension in their ﬁrst pregnancy 10450371 5194 1.0 (reference)
Pre-eclampsia and/or hypertension in ﬁrst pregnancy 663311 280 0.81 0.71–0.91
aAdjusted for attained age (530, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–80), calendar period of diagnoses (1967–76, 1977–86, 1987–98), age at ﬁrst
birth (520, 20–24, 25–29, 30–34, 35–54), and parity (1, 2, 3, 4, 5–16).
bCI=conﬁdence interval
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